FDA Grants Accelerated Approval to Atrasentan for Proteinuria Reduction in Primary IgA Nephropathy
April 3rd 2025Positive results from an interim analysis of the phase 3 ALIGN study bolstered atrasentan towards receiving accelerated approval for patients with immunoglobulin A nephropathy, a rare condition that can cause kidney failure.
Read More
ELCC 2025: Amivantamab Plus Lazertinib Effective in EGFR-Mutated NSCLC Versus Standard of Care
April 2nd 2025Nicolas Girard, MD, explains the benefits observed in the MARIPOSA clinical trial among patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated with amivantamab plus lazertinib.
Watch
Revolutionizing Treatment with Bispecific Therapies: Navigating the Challenges Ahead
April 2nd 2025By decade’s end, approval of additional bispecifics is expected for hematological malignancies, solid tumors, and non-oncology conditions such as inflammatory, autoimmune, neurodegenerative and vascular diseases, and ocular disorders and infections.
Read More
Everything You Need to Know From the American College of Cardiology 2025 Scientific Session
Host Craig Beavers spoke with several presenters, researchers, and experts about the key data being discussed at the meeting.
Listen